The successful Phase 3 trial of Reproxalap ophthalmic solution for allergic conjunctivitis indicates that the product is effective and may lead to regulatory approval. This positive news is likely to increase investor confidence in Aldeyra Therapeutics, potentially driving up the stock price in the short term.